Drugs / VBI-2901a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05548439 | Oct 2022 → Jan 2024 | COVID-19 | VBI Vaccines Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VBI-2901a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05548439 ↗ |
| Modality | Vaccine | “VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs)” NCT05548439 ↗ |
| Route | Intramuscular | “Intramuscular injection of VBI-2901a” NCT05548439 ↗ |